Morris S. Berrie
Dr. Morris S. Berrie is Co-Chairman of TTS Ltd and Managing Director of Tech Investor Ltd. The former is an organization that globally facilitates deal flow in TTO / the early stage start-up / SME biotech sector whilst the latter specifically aids and advises Govs and companies throughout the biotech sector on ‘the business of science’, i.e. business development, strategy, licensing and capital raising. Prior to these roles he was both the Chief Executive Officer and Editor-in-Chief of the Biotechnology Investment Group and during this period he worked with prestigious clients including: US National Institutes of Health (NIH), InvestAustralia, Trade Canada, UBS, JPMorgan, Wachovia, Nomura, Deutsche Bank, Morgan Stanley, TVM, Orbimed, SGCowen, MPM, Hambrecht&Quist Capital Management, Pfizer, GSK, Merck, BMS, J&J, Eli Lilly and AstraZeneca. He has also consulted for several well-known companies operating in the life science and media sectors. Previously he was Head of Global Intelligence and Business Development for Nature Publishing Group and responsible for the research and development of key product launches and the organization of the Business Intelligence Seminars. Dr. Berrie originally began his career at Current Drugs (now Thomson Reuters) where he managed the life science patent and drug registry content of the Investigational Drug database (IDdb). He has worked at Schering AG, GlaxoWellcome, is a Chartered Chemist (CChem), a Member of the Royal Society of Chemistry (MRSC) and was the recipient of a European DG Post-Doctoral Fellowship upon completing his Ph.D. at Imperial College, London. He also sits on the Business Strategy, Publishing and Awards Committees of the Royal Society of Chemical Industry.
Christian J. Suojanen
Christian is Co-Chairman of TTS Ltd and Partner, Head of Life Sciences at Valor Management S.A., through which he serves as a strategic adviser in the biotech sector, to funds, CEOs, companies, TTOs, and governments. With a focus on Europe, North America and the BRIC countries, his specializations are in licensing, strategic business development, fund-raising, and capital formation, selectively accepting a small number of mandates and supporting these closely, often in an acting or virtual management role focused on finance and business development.
As a turn-around engagement as Executive Board member and Secretary General, he revived Europe’s largest biotech association and rebuilt membership, developed strong international relations with relevant organizations, increased revenues, launched new member services and Public Affairs initiatives at the European level, re-branded and successfully relaunched a fading international scientific congress, and negotiated the creation of an official society journal with a leading publisher. He also serves on the Finance Committee of the Think Tank EPPOSI (European Platform for Patients Organizations, Science & Industry), and on the Editorial Board of New Biotechnology (Elsevier). Prior to that, as Executive Director of a European provider of deal origination and investment services to tech investors and entrepreneurs, he led the development of new business activities in the life sciences sector, working extensively with leading venture capital funds, legal and consulting firms, European, national and regional development agencies, and entrepreneurs across Europe.
Christian speaks English, French & Spanish.